With the aid of a four-year, $3.4 million grant from the National Institute of Mental Health, researchers at Vanderbilt University Medical Center and Massachusetts General Hospital (MGH) will apply new techniques to investigate treatment resistance of two devastating mental disorders — major depressive disorder, which befalls 15 percent of people at some point in their lives, and schizophrenia, which affects approximately 1 percent.

Targeting the immune system may provide a new avenue for therapeutic intervention in psychiatric diseases characterized by motivational and cognitive deficits.

A Vanderbilt University Medical Center pilot study of treating late-life depression in nonsmokers with transdermal nicotine (nicotine patch) has yielded some promising results, but the study’s author cautions that more study is needed.

Symptoms of schizophrenia and bipolar disorder, including psychosis, depression and manic behavior, have both shared and distinguishing genetic factors, an international consortium led by researchers from Vanderbilt University and Virginia Commonwealth University is reporting.

Jonathan Becker, DO, the medical director overseeing Vanderbilt Psychiatric Hospital’s electroconvulsive therapy (ECT) program, spends a fair amount of time explaining to patients what electroconvulsive therapy is not.

Clinicians should use a structured interview in people with Alzheimer’s disease to identify pain that might be otherwise overlooked.

Women who have had repeated depressive episodes tend to pay more attention to negative emotional information, suggesting that they may benefit from cognitive therapy to build new, more positive pathways in their brains.